Vega Therapeutics, Inc
Quick facts
Phase 3 pipeline
- VGA039 · Diabetes
VGA039 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: